MoonLake Immunotherapeutics (MLTX) Total Current Liabilities (2020 - 2026)

MoonLake Immunotherapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $46.1 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 92.29% year-over-year to $46.1 million in Q1 2026; TTM through Mar 2026 was $46.1 million, a 92.29% increase from a year earlier, with the FY2025 full-year figure at $45.5 million, up 102.46% from the prior year.
• Total Current Liabilities grew to $46.1 million in Q1 2026 per MLTX's latest filing, from $45.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $202.8 million in Q1 2022 and bottomed at $3.9 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $12.3 million (2024), against an average of $30.0 million.
• Across the five-year window, Total Current Liabilities surged 337883.77% in 2022 and tumbled 96.41% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $7.7 million in 2022, then jumped by 30.01% to $10.0 million in 2023, then soared by 125.4% to $22.5 million in 2024, then jumped by 102.46% to $45.5 million in 2025, then gained by 1.4% to $46.1 million in 2026.
• Per Business Quant, the three latest MLTX Total Current Liabilities figures stand at $46.1 million (Q1 2026), $45.5 million (Q4 2025), and $48.4 million (Q3 2025).